News
First-in-class diabetes drug recommended for FDA approval
AstraZeneca and Bristol-Myers Squibb have received a positive opinion from an FDA committee for dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor developed through an allian
